- Home
- CSIQ vs GYRE Comparison
CSIQ vs GYRE Comparison
Compare CSIQ & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSIQ | GYRE |
|---|---|---|
| Founded | 2001 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.4M | 679.4M |
| IPO Year | 2006 | 2004 |
Fundamental Metrics
Financial Performance| Metric | CSIQ | GYRE |
|---|---|---|
| Price | $16.49 | $7.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 2 |
| Target Price | ★ $17.36 | $17.00 |
| AVG Volume (30 Days) | ★ 2.4M | 44.6K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $275,000.00 |
| Revenue This Year | $23.61 | $19.88 |
| Revenue Next Year | $13.90 | N/A |
| P/E Ratio | ★ N/A | $384.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.84 | $6.58 |
| 52 Week High | $34.59 | $11.77 |
Technical Indicators
Market Signals| Indicator | CSIQ | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 54.13 |
| Support Level | $15.93 | $7.25 |
| Resistance Level | $17.07 | $7.91 |
| Average True Range (ATR) | 1.14 | 0.26 |
| MACD | 0.49 | 0.00 |
| Stochastic Oscillator | 93.72 | 52.22 |
Price Performance
Historical ComparisonAbout CSIQ Canadian Solar Inc. (ON)
Canadian Solar Inc is a Canadian solar technology and renewable energy company. It is a manufacturer of solar photovoltaic modules, a provider of battery energy storage solutions, and a developer of utility-scale solar power and battery energy storage projects.. It operates through two business segments CSI Solar and Recurrent Energy segment. The CSI Solar segment focused on solar modules and battery energy storage manufacturing and products. Its Recurrent segment focused on utility-scale solar power and battery energy storage project development and operation. Key revenue is generated from CSI Solar segment.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.